Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
ASTRAZENECA PHARMACEUTICALS LP et al v. MYLAN PHARMACEUTICALS INC. et al
Case Number:
1:15-cv-07009
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
December 03, 2015
AstraZeneca Defends NJ Venue In Breast Cancer Drug Row
AstraZeneca AB blasted Mylan Laboratories Ltd.'s contention that New Jersey is the wrong venue for a patent infringement lawsuit over AstraZeneca's breast cancer drug, arguing Wednesday that it was the generic-drug maker's Garden State subsidiary that filed the application to market its version of the drug.
-
November 25, 2015
AstraZeneca's Cancer Drug Suit In Wrong Venue, Mylan Says
Mylan Pharmaceuticals Inc. has said it will ask a New Jersey federal judge to dismiss AstraZeneca's patent suit over the generic-drug maker's attempt to market a generic version of its Faslodex breast cancer treatment, arguing the court lacks jurisdiction in the case because the parties involved have no connection to New Jersey.
-
September 23, 2015
AstraZeneca Hits Mylan With Patent Suit Over Cancer Generic
Pharmaceutical giant AstraZeneca hit generic-drug maker Mylan Inc. with a patent infringement suit in New Jersey federal court Monday, aiming to halt production of a generic version of the breast cancer drug Faslodex.